Compare Cytokinetics Inc (CYTK) vs Five Below Inc (FIVE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Five Below Inc — how do they compare? Cytokinetics Inc trades at $81.44 (market cap $11.12B), while Five Below Inc trades at $193.25 (market cap $10.68B). The key difference: Cytokinetics Inc and Five Below Inc are close in size by market cap, and Cytokinetics Inc is trading nearer its 52-week high, Five Below Inc nearer its low. Which is the better fit depends on your goals.
| CYTK | FIVE | |
|---|---|---|
Market Cap | $11.12B | $10.68B |
Sector | Technology | Consumer Staples |
52-Week High | $87.26 | $247.71 |
52-Week Low | $33.23 | $131.94 |
Enterprise Value | $11.59B | $11.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
Five Below (FIVE) trades at $191.53, up 1.13% on the day, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 21.13% ROE and 8.67% net margin, supported by revenue growth from $3.6B in 2024 to $3.9B in 2025. Recent milestones include opening its 2,000th store and leadership appointments, driving positive media coverage.
The outlook remains positive with a $252.09 analyst price target implying 31% upside, though risks include volatile cash flows and competitive pressures. Earnings momentum and digital marketing investments position FIVE for growth, but investors should monitor execution against 2026's $5.1B revenue target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Five Below Inc
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →
